<table border="1" frame="box" id="table_10" rules="all" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 10. Drug Interactions:  Pharmacokinetic Parameters for Lopinavir in the Presence of the Co-administered Drug for Recommended Alterations in Dose or Regimen</caption>
<colgroup>
<col stylecode="Lrule Rrule Toprule Botrule" width="17%"></col>
<col stylecode="Lrule Rrule Toprule Botrule" width="17%"></col>
<col stylecode="Lrule Rrule Toprule Botrule" width="14%"></col>
<col stylecode="Lrule Rrule Toprule Botrule" width="8%"></col>
<col stylecode="Lrule Rrule Toprule Botrule" width="13%"></col>
<col stylecode="Lrule Rrule Toprule Botrule" width="13%"></col>
<col stylecode="Lrule Rrule Toprule Botrule" width="0%"></col>
<col stylecode="Lrule Rrule Toprule Botrule" width="13%"></col>
</colgroup>
<thead>
<tr valign="bottom">
<td>
<content stylecode="bold">Co-administered Drug</content>
</td>
<td align="center">
<content stylecode="bold">Dose of Co-administered Drug                      <br/>(mg)</content>
</td>
<td align="center">
<content stylecode="bold">Dose of KALETRA                      <br/>(mg)</content>
</td>
<td align="center"></td>
<td align="center" colspan="4">
<content stylecode="bold">Ratio (in combination with co-administered drug/alone) of Lopinavir Pharmacokinetic Parameters (90% CI); No Effect = 1.00</content>
</td>
</tr>
<tr valign="bottom">
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center">
<content stylecode="bold">n </content>
</td>
<td align="center">
<content stylecode="bold">C<sub>max</sub>
</content>
</td>
<td align="center">
<content stylecode="bold">AUC</content>
</td>
<td align="center" colspan="2">
<content stylecode="bold">C<sub>min</sub>
</content>
</td>
</tr>
</thead>
<tfoot>
<tr stylecode="Lrule Rrule Toprule Botrule">
<td colspan="8">
<paragraph>All interaction studies conducted in healthy, HIV-1 negative subjects unless otherwise indicated.</paragraph>
<paragraph>1   The pharmacokinetics of ritonavir are unaffected by concurrent efavirenz.</paragraph>
<paragraph>2   Data extracted from the fosamprenavir package insert.</paragraph>
<paragraph>3   Study conducted in HIV-1 positive adult subjects.</paragraph>
<paragraph>4   Study conducted in HIV-1 positive pediatric subjects ranging in age from 6 months to 12 years.</paragraph>
<paragraph>5   Titrated to 800/200 twice daily as 533/133 twice daily x 1 d, 667/167 twice daily x 1 d, then 800/200 twice daily x 7 d, compared to 400/100 twice daily x 10 days alone.</paragraph>
<paragraph>6   Titrated to 400/400 twice daily as 400/200 twice daily x 1 d, 400/300 twice daily x 1 d, then 400/400 twice daily x 7 d, compared to 400/100 twice daily x 10 days alone.</paragraph>
<paragraph>7   Data extracted from the tenofovir package insert.</paragraph>
<paragraph>8   Intensive PK analysis.</paragraph>
<paragraph>9   Drug levels obtained at 8-16 hrs post-dose.</paragraph>
<paragraph>10  Reference for comparison is lopinavir/ritonavir 400/100 mg twice daily without efavirenz.</paragraph>
<paragraph>*   Parallel group design; n for KALETRA + co-administered drug, n for KALETRA alone.</paragraph>
<paragraph>†   NC = No change.</paragraph>
<paragraph># For the nevirapine 200 mg twice daily study, ritonavir, and tipranavir/ritonavir studies, KALETRA was administered with or without food.  For all other studies, KALETRA was administered with food.</paragraph>
</td>
</tr>
</tfoot>
<tbody>
<tr stylecode="Lrule Rrule Toprule Botrule">
<td>Amprenavir</td>
<td align="center">750 twice daily, 10 d</td>
<td align="center">400/100 capsule twice daily, 21 d</td>
<td align="center">12</td>
<td align="center">0.72<br/>(0.65, 0.79)</td>
<td align="center">0.62<br/>(0.56, 0.70)</td>
<td align="center" colspan="2">0.43<br/>(0.34, 0.56)</td>
</tr>
<tr stylecode="Lrule Rrule Toprule Botrule">
<td>Efavirenz<sup>1,10</sup>
</td>
<td align="center">600 at bedtime, 9 d										</td>
<td align="center">400/100 capsule twice daily, 9 d</td>
<td align="center">11, 7*</td>
<td align="center">0.97<br/>(0.78, 1.22)</td>
<td align="center">0.81<br/>(0.64, 1.03)</td>
<td align="center" colspan="2">0.61<br/>(0.38, 0.97)</td>
</tr>
<tr stylecode="Lrule Rrule Toprule Botrule">
<td></td>
<td align="center">600 at bedtime, 9 d</td>
<td align="center">500/125 tablet <br/>twice daily, 10 d</td>
<td align="center">19</td>
<td align="center">1.12<br/>(1.02, 1.23)</td>
<td align="center">1.06<br/>(0.96, 1.17)</td>
<td align="center" colspan="2">0.90<br/>(0.78, 1.04)</td>
</tr>
<tr stylecode="Lrule Rrule Toprule Botrule">
<td></td>
<td align="center">600 at bedtime, 9 d</td>
<td align="center">600/150 tablet<br/> twice daily, 10 d </td>
<td align="center">23</td>
<td align="center">1.36<br/>(1.28, 1.44)</td>
<td align="center">1.36<br/>(1.28, 1.44)</td>
<td align="center" colspan="2">1.32<br/>(1.21, 1.44)</td>
</tr>
<tr stylecode="Lrule Rrule Toprule Botrule">
<td>Fosamprenavir<sup>2</sup>
</td>
<td align="center">700 twice daily plus ritonavir 100 twice daily, 14 d</td>
<td align="center">400/100 capsule twice daily, 14 d</td>
<td align="center">18</td>
<td align="center">1.30<br/>(0.85, 1.47)</td>
<td align="center">1.37<br/>(0.80, 1.55)</td>
<td align="center" colspan="2">1.52<br/>(0.72, 1.82)</td>
</tr>
<tr stylecode="Lrule Rrule Toprule Botrule">
<td>Ketoconazole</td>
<td align="center">200 single dose</td>
<td align="center">400/100 capsule twice daily, 16 d</td>
<td align="center">12</td>
<td align="center">0.89<br/>(0.80, 0.99)</td>
<td align="center">0.87<br/>(0.75, 1.00)</td>
<td align="center" colspan="2">0.75<br/>(0.55, 1.00)</td>
</tr>
<tr stylecode="Lrule Rrule Toprule Botrule">
<td>Nelfinavir</td>
<td align="center">1000 twice daily, <br/>10 d</td>
<td align="center">400/100 capsule twice daily, 21 d</td>
<td align="center">13</td>
<td align="center">0.79<br/>(0.70, 0.89)</td>
<td align="center">0.73<br/>(0.63, 0.85)</td>
<td align="center" colspan="2">0.62<br/>(0.49, 0.78)</td>
</tr>
<tr stylecode="Lrule Rrule Toprule Botrule">
<td>Nevirapine</td>
<td align="center">200 twice daily, steady-state<br/> (&gt; 1 yr)<sup>3#</sup>
</td>
<td align="center">400/100 capsule twice daily,<br/> steady-state</td>
<td align="center">22, 19*</td>
<td align="center">0.81<br/>(0.62, 1.05)</td>
<td align="center">0.73<br/>(0.53, 0.98)</td>
<td align="center" colspan="2">0.49<br/>(0.28, 0.74)</td>
</tr>
<tr stylecode="Lrule Rrule Toprule Botrule">
<td></td>
<td align="center">7 mg/kg or 4 mg/kg once daily, 2 wk; twice daily 1 wk<sup>4</sup>
</td>
<td align="center">(&gt; 1 yr) 300/75 mg/m<sup>2</sup>
<br/>oral solution<br/> twice daily, 3 wk</td>
<td align="center">12, 15*</td>
<td align="center">0.86<br/>(0.64, 1.16)</td>
<td align="center">0.78<br/>(0.56, 1.09)</td>
<td align="center" colspan="2">0.45<br/>(0.25, 0.81)</td>
</tr>
<tr>
<td>Omeprazole</td>
<td align="center">40 once daily, 5 d</td>
<td align="center">400/100 tablet twice daily, 10 d</td>
<td align="center">12</td>
<td align="center">1.08<br/>(0.99, 1.17)</td>
<td align="center">1.07<br/>(0.99, 1.15)</td>
<td align="center" colspan="2">1.03<br/>(0.90, 1.18)</td>
</tr>
<tr>
<td></td>
<td align="center">40 once daily, 5 d</td>
<td align="center">800/200 tablet once daily, 10 d</td>
<td align="center">12</td>
<td align="center">0.94<br/>(0.88, 1.00)</td>
<td align="center">0.92<br/>(0.86, 0.99)</td>
<td align="center" colspan="2">0.71<br/>(0.57, 0.89)</td>
</tr>
<tr>
<td>Pravastatin </td>
<td align="center">20 once daily, 4 d</td>
<td align="center">400/100 capsule twice daily, 14 d</td>
<td align="center">12</td>
<td align="center">0.98<br/>(0.89, 1.08)</td>
<td align="center">0.95<br/>(0.85, 1.05)</td>
<td align="center" colspan="2">0.88<br/>(0.77, 1.02)</td>
</tr>
<tr>
<td>Rifabutin</td>
<td align="center">150 once daily, 10 d</td>
<td align="center">400/100 capsule twice daily, 20 d</td>
<td align="center">14</td>
<td align="center">1.08<br/>(0.97, 1.19)</td>
<td align="center">1.17<br/>(1.04, 1.31)</td>
<td align="center" colspan="2">1.20<br/>(0.96, 1.65)</td>
</tr>
<tr>
<td>Ranitidine</td>
<td align="center">150 single dose</td>
<td align="center">400/100 tablet twice daily, 10 d</td>
<td align="center">12</td>
<td align="center">0.99<br/>(0.95, 1.03)</td>
<td align="center">0.97<br/>(0.93, 1.01)</td>
<td align="center" colspan="2">0.90<br/>(0.85, 0.95)</td>
</tr>
<tr>
<td></td>
<td align="center">150 single dose</td>
<td align="center">800/200 tablet once daily, 10 d</td>
<td align="center">10</td>
<td align="center">0.97<br/>(0.95, 1.00)</td>
<td align="center">0.95<br/>(0.91, 0.99)</td>
<td align="center" colspan="2">0.82<br/>(0.74, 0.91)</td>
</tr>
<tr>
<td>Rifampin</td>
<td align="center">600 once daily,<br/>10 d</td>
<td align="center">400/100 capsule twice daily, 20 d</td>
<td align="center">22</td>
<td align="center">0.45<br/>(0.40, 0.51)</td>
<td align="center">0.25<br/>(0.21, 0.29)</td>
<td align="center" colspan="2">0.01<br/>(0.01, 0.02)</td>
</tr>
<tr>
<td></td>
<td align="center">600 once daily,<br/>14 d</td>
<td align="center">800/200 capsule twice daily, 9 d<sup>5</sup>
</td>
<td align="center">10</td>
<td align="center">1.02<br/>(0.85, 1.23)</td>
<td align="center">0.84<br/>(0.64, 1.10)</td>
<td align="center" colspan="2">0.43<br/>(0.19, 0.96)</td>
</tr>
<tr>
<td></td>
<td align="center">600 once daily,<br/>14 d</td>
<td align="center">400/400 capsule twice daily, 9 d<sup>6</sup>
</td>
<td align="center">9</td>
<td align="center">0.93<br/>(0.81, 1.07)</td>
<td align="center">0.98<br/>(0.81, 1.17)</td>
<td align="center" colspan="2">1.03<br/>(0.68, 1.56)</td>
</tr>
<tr>
<td></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center" colspan="3">Co-administration of KALETRA and rifampin is contraindicated.<br/>
<content stylecode="italics">[see Contraindications ( <linkhtml href="#section_4">4</linkhtml>)]</content>
</td>
</tr>
<tr>
<td>Ritonavir<sup>3</sup>
</td>
<td align="center">100 twice daily,<br/>3-4 wk<sup>#</sup>
</td>
<td align="center">400/100 capsule twice daily,<br/>3-4 wk</td>
<td align="center">8, 21*</td>
<td align="center">1.28<br/>(0.94, 1.76)</td>
<td align="center" colspan="2">1.46<br/>(1.04, 2.06)</td>
<td align="center">2.16<br/>(1.29, 3.62)</td>
</tr>
<tr>
<td>Tenofovir<sup>7</sup>
</td>
<td align="center">300 mg once daily, <br/>14 d</td>
<td align="center">400/100 capsule twice daily, 14 d</td>
<td align="center">24</td>
<td align="center">NC<sup>†</sup>
</td>
<td align="center" colspan="2">NC<sup>†</sup>
</td>
<td align="center">NC<sup>†</sup>
</td>
</tr>
<tr>
<td>Tipranavir/ritonavir<sup>3</sup>
</td>
<td align="center">500/200 mg twice daily (28 doses)<sup>#</sup>
</td>
<td align="center">400/100 capsule twice daily<br/> (27 doses)</td>
<td align="center">21<paragraph></paragraph>
<paragraph></paragraph>69</td>
<td align="center">0.53<br/>(0.40, 0.69)<sup>8</sup>
</td>
<td align="center" colspan="2">0.45<br/>(0.32, 0.63)<sup>8</sup>
</td>
<td align="center">0.30 (0.17, 0.51)<sup>8</sup>
<paragraph></paragraph>
<paragraph></paragraph>0.48 (0.40, 0.58)<sup>9</sup>
</td>
</tr>
</tbody>
</table>